Improved heterologous erythromycin A production through expression plasmid re-design
Ming Jiang1, Lei Fang, Blaine A Pfeifer
1State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Biotechnology Progress
|June 28, 2013
Summary
This study engineered Escherichia coli for improved erythromycin A production by optimizing gene expression plasmids, reducing metabolic burden and instability. The enhanced system achieved a 5-fold increase in antibiotic compound yield.
Area of Science:
- Synthetic biology
- Metabolic engineering
- Microbial biotechnology
Background:
- Erythromycin A is a vital antibiotic traditionally produced by Saccharopolyspora erythraea.
- Heterologous production in Escherichia coli offers a scalable alternative but faces challenges like metabolic burden and plasmid instability.
- Previous E. coli systems utilized 20 genes on multiple plasmids, hindering efficient biosynthesis.
Purpose of the Study:
- To engineer a more efficient erythromycin A production system in Escherichia coli.
- To reduce metabolic burden and improve plasmid stability in the host organism.
- To enhance the overall yield of erythromycin A through pathway and expression optimization.
Main Methods:
- Streamlined the erythromycin biosynthetic pathway by reducing the number of genes and expression plasmids.
- Investigated the impact of species-specific protein chaperonins (E. coli vs. S. coelicolor) on host performance.
- Implemented optimized expression strategies to mitigate metabolic load and enhance plasmid retention.
Main Results:
- The redesigned expression platform significantly reduced metabolic burden and improved plasmid stability.
- Species-specific chaperonins demonstrated differential effects on microbial growth and plasmid maintenance.
- Erythromycin A production titers were increased by 5-fold compared to previous E. coli-based systems.
Conclusions:
- Optimized expression plasmid design is crucial for successful heterologous natural product biosynthesis.
- Engineering efforts successfully upgraded the E. coli erythromycin A production platform.
- Further pathway engineering holds potential for even greater improvements in heterologous compound production.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...